ADMA Biologics addresses Culper Research short-seller report; review of assertions begins

ADMA Biologics, Inc. +2.51% Pre

ADMA Biologics, Inc.

ADMA

11.01

10.95

+2.51%

-0.54% Pre
  • ADMA Biologics said a Culper Research report issued March 24, 2026 contains numerous misleading, false and inaccurate statements.
  • The company said the report appears based on speculative assertions from unidentified and unreliable sources.
  • ADMA Biologics said it takes its obligations to report operating and financial results and make public disclosures in accordance with U.S. SEC rules and U.S. GAAP seriously.
  • The company said it is taking appropriate steps to review the report’s assertions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADMA Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603250630PRIMZONEFULLFEED9678215) on March 25, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.